News

Last November, Dr. Piera Pasinelli, Ph.D., associate professor of neuroscience and Co-Director of the Weinberg Unit for ALS Research at Thomas Jefferson University, and her research team made an important discovery in the field of amyotrophic lateral sclerosis (ALS) research that may change the way the therapeutic protocols…

A new study entitled “HDAC6 Is a Bruchpilot Deacetylase that Facilitates Neurotransmitter Release” was published in Cell Reports by Katarzyna Miskiewicz and Liya E. Jose, co-first authors of the study and part of Dr. Patrik Verstreken’s group from the VIB Center for the…

Researchers at The Scripps Research Institute in California found that a particular enzyme has a harmful ability to create inflammatory lipid molecules in the brain, and is implicated in a rare neuroimmunological disorder, called PHARC – characterized by polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract. The disorder usually begins onset during adolescence and gradually gets worse with…

Newron Pharmaceuticals is about to initiate its Phase II clinical trial, designed to evaluate novel molecule sNN0029 in patients who suffer from Amyotrophic Lateral Sclerosis (ALS), according to information provided by the company in a press release. The company, which has been dedicated to providing CNS…

A new study entitled “Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis” suggests that further studies are needed to understand if supplementing Vitamin D in patients with amyotrophic lateral sclerosis is capable of delaying disease progression. The study is published in the…

Treeway, a biotechnological company based in the Netherlands, founded by Bernard Muller and Robbert Jan Stuit, who are both entrepreneurs and both diagnosed with amyotrophic lateral sclerosis (ALS), recently announced a collaboration with uniQure, a Dutch company specialized in gene therapy to develop a treatment for the disease.

AB Science SA, a pharmaceutical company focused on research, advancement and commercialization of protein kinase inhibitors (PKIs) announced that the external Data and Safety Monitoring Board (DSMB) recommended the company’s phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) be continued. The decision was supported by the drug’s latest safety reports. The current…

New York and Israel-based, BrainStorm Cell Therapeutics, Inc., announced positive final results from a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS). The study reached its main goal, showing that NurOwn™ is safe and well-tolerated. In addition, the majority of the 14 participants in this study had an improvement (slowing)…

NEALS will be holding its first annual Virtual ALS Clinical Research Learning Institute (CRLI) this month, January 2015, that will discuss amyotrophic lateral sclerosis (ALS). The ALS CRLI will be sponsored by the ALS Association’s TREAT ALS initiative. The ALS Clinical Research Learning Institute is an intensive program whose goal is to educate…

A new study on amyotrophic lateral sclerosis (ALS), entitled, “ATXN2 polyQ intermediate repeats are a modifier of ALS survival” published in Neurology by Dr. A. Chiò from the ALS Center, Department of Neuroscience, University of Torino in Italy, evaluated the rate of…